PMID- 7582456
OWN - NLM
STAT- MEDLINE
DCOM- 19951127
LR  - 20201209
IS  - 0007-1188 (Print)
IS  - 0007-1188 (Linking)
VI  - 115
IP  - 3
DP  - 1995 Jun
TI  - Dose-response comparisons of five lung surfactant factor (LSF) preparations in an 
      animal model of adult respiratory distress syndrome (ARDS).
PG  - 451-8
AB  - 1. We have examined the effects of five different lung surfactant factor (LSF) 
      preparations in the rat lung lavage model. In this model repetitive lung lavage 
      leads to lung injury with some similarities to adult respiratory distress 
      syndrome with poor gas exchange and protein leakage into the alveolar spaces. 
      These pathological sequelae can be reversed by LSF instillation soon after 
      lavage. 2. The tested LSF preparations were: two bovine: Survanta and Alveofact: 
      two synthetic: Exosurf and a protein-free phospholipid based LSF (PL-LSF) and one 
      Recombinant LSF at doses of 25, 50 and 100 mg kg-1 body weight and an untreated 
      control group. 3. Tracheotomized rats (10-12 per dose) were pressure-controlled 
      ventilated (Siemens Servo Ventilator 900C) with 100% oxygen at a respiratory rate 
      of 30 breaths min-1, inspiration expiration ratio of 1:2, peak inspiratory 
      pressure (PIP) of 28 cmH2O at positive end-expiratory pressure (PEEP) of 8 cmH2O. 
      Two hours after LSF administration, PEEP and in parallel PIP was reduced from 8 
      to 6 (1st reduction), from 6 to 3 (2nd reduction) and from 3 to 0 cmH2O (3rd 
      reduction). 4. Partial arterial oxygen pressure (PaO2, mmHg) at 5 min and 120 min 
      after LSF administration and during the 2nd PEEP reduction (PaO2(PEEP23/3)) were 
      used for statistical comparison. All LSF preparations caused a dose-dependent 
      increase for the PaO2(120'), whereas during the 2nd PEEP reduction only bovine 
      and recombinant LSF exhibited dose-dependency. Exosurf did not increase PaO2 
      after administration of the highest dose. At the highest dose Exosurf exerted no 
      further improvement but rather a tendency to relapse. The bovine and the 
      Recombinant LSF are superior to both synthetic LSFpreparations.5. In this animal 
      model and under the described specific ventilatory settings, even between bovine 
      LSFpreparations there are detectable differences that are pronounced when 
      compared to synthetic LSFwithout any surfactant proteins. We conclude that the 
      difference between bovine and synthetic LSFpreparations can be overcome by 
      addition of the surfactant protein C.
FAU - Hafner, D
AU  - Hafner D
AD  - Byk Gulden, Department of Respiratory Pharmacology, Konstanz, Germany.
FAU - Beume, R
AU  - Beume R
FAU - Kilian, U
AU  - Kilian U
FAU - Krasznai, G
AU  - Krasznai G
FAU - Lachmann, B
AU  - Lachmann B
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Br J Pharmacol
JT  - British journal of pharmacology
JID - 7502536
RN  - 0 (Biological Products)
RN  - 0 (Drug Combinations)
RN  - 0 (Fatty Alcohols)
RN  - 0 (Lipids)
RN  - 0 (Phospholipids)
RN  - 0 (Pulmonary Surfactants)
RN  - 0 (Recombinant Proteins)
RN  - 0 (SF-RI 1, bovine surfactant preparation)
RN  - 107-73-3 (Phosphorylcholine)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 99732-49-7 (dipalmitoylphosphatidylcholine, hexadecanol, tyloxapol drug 
      combination)
RN  - S866O45PIG (beractant)
SB  - IM
MH  - Animals
MH  - *Biological Products
MH  - Blood Gas Analysis
MH  - Cattle
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Fatty Alcohols/administration & dosage/pharmacology/therapeutic use
MH  - Feasibility Studies
MH  - Lipids/administration & dosage/pharmacology/therapeutic use
MH  - Male
MH  - Partial Pressure
MH  - *Phospholipids
MH  - *Phosphorylcholine
MH  - Polyethylene Glycols/administration & dosage/pharmacology/therapeutic use
MH  - Positive-Pressure Respiration
MH  - Pulmonary Alveoli/drug effects
MH  - Pulmonary Gas Exchange/*drug effects
MH  - Pulmonary Surfactants/administration & dosage/pharmacology/*therapeutic use
MH  - Pulmonary Wedge Pressure/drug effects
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Recombinant Proteins/pharmacology/therapeutic use
MH  - Respiratory Distress Syndrome/*drug therapy
MH  - Trachea/drug effects
PMC - PMC1908419
EDAT- 1995/06/01 00:00
MHDA- 1995/06/01 00:01
PMCR- 1996/06/01
CRDT- 1995/06/01 00:00
PHST- 1995/06/01 00:00 [pubmed]
PHST- 1995/06/01 00:01 [medline]
PHST- 1995/06/01 00:00 [entrez]
PHST- 1996/06/01 00:00 [pmc-release]
AID - 10.1111/j.1476-5381.1995.tb16354.x [doi]
PST - ppublish
SO  - Br J Pharmacol. 1995 Jun;115(3):451-8. doi: 10.1111/j.1476-5381.1995.tb16354.x.